NLRP3 and cryopyrin-associated periodic syndrome: Small-molecule inhibitors targeting the NLRP3 inflammasome promise a therapeutic benefit for a wide range of immune diseases including the CAPS mutant associated Muckle-Wells-Syndrome50.